Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Motor neuron disease

A prospective natural history study of type 1 spinal muscular atrophy

Effective drug development for infantile-onset spinal muscular atrophy (SMA) requires a meaningful understanding of disease progression and reliable biomarkers. A new report presents the results of a longitudinal, multicentre, prospective natural history study of SMA, which are critical for the research of future therapies.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kolb, S. J. et al. Natural history of infantile-onset spinal muscular atrophy. Ann. Neurol. 82, 883–891 (2017).

    Article  CAS  Google Scholar 

  2. Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713–1722 (2017).

    Article  CAS  Google Scholar 

  3. Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular strophy. N. Engl. J. Med. 377, 1723–1732 (2017).

    Article  CAS  Google Scholar 

  4. Finkel, R. S. et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 83, 810–817 (2014).

    Article  Google Scholar 

  5. Mercuri, E., Bertini, E. & Iannaccone, S. T. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 11, 443–452 (2012).

    Article  Google Scholar 

  6. Zerres, K. & Rudnik-Schoneborn, S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch. Neurol. 52, 518–523 (1995).

    Article  CAS  Google Scholar 

  7. De Sanctis, R. et al. Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy. Neuromuscular Disord. https://doi.org/10.1016/j.nmd.2017.09.015 (2017).

    Article  Google Scholar 

  8. De Sanctis, R. et al. Developmental milestones in type I spinal muscular atrophy. Neuromuscular Disord. 26, 754–759 (2016).

    Article  Google Scholar 

  9. Feldkotter, M. et al. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am. J. Hum. Genet. 70, 358–368 (2002).

    Article  CAS  Google Scholar 

  10. Finkel, R. et al. 209th ENMC international workshop: outcome measures and clinical trial readiness in spinal muscular atrophy 7–9 November 2014, Heemskerk, The Netherlands. Neuromuscular Disord. 25, 593–602 (2015).

    Article  Google Scholar 

  11. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02386553 (2017).

Download references

Author information

Authors and Affiliations

Authors

Contributions

E.B. researched data for and wrote the article. Both E.B. and E.M. carried out discussions of the content and the review/editing of the manuscript.

Corresponding author

Correspondence to Enrico Bertini.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bertini, E., Mercuri, E. A prospective natural history study of type 1 spinal muscular atrophy. Nat Rev Neurol 14, 197–198 (2018). https://doi.org/10.1038/nrneurol.2017.189

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2017.189

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing